Efficacy and safety of biphasic insulin aspart 30 in the treatment of diabetic patients: a multicenter, randomized, open-labeled controlled trial
李延兵,吕肖锋,叶山东,周智广,余学锋,文重远,莫朝晖,赵维纲,杨金奎,肖常青,王长江,任艳,刘红,孙皎,陆菊明,张力辉,石勇铨,李玲,栾健,张莹
DOI: https://doi.org/10.3760/cma.j.cn115791-20200513-00279
2021-01-01
Abstract:Objective:To explore the efficacy and safety of biphasic insulin aspart 30 (UBLIN ?30) in treatment of diabetic patients. Methods:A multicenter, randomized, open-labeled and positive control clinical trial included the patients with type 1 or type 2 diabetes mellitus having poor glucose control after using premixed insulin monotherapy or combine with 1 or 2 oral antidiabetic drugs. All patients were treated with UBLIN ?30 or NovoMix ?30 for 24 weeks in two groups by a ratio of 1∶1. The decreased value and qualification rates of glycated hemoglobin A 1c(HbA 1c), fasting blood glucose (FPG) and 2-hour postprandial plasma glucose (2hPG), the incidence of hypoglycemic and the adverse events were compared at the end of 24 weeks. Analysis of variance (ANOVA) test, t test and Wilcoxon test were used. Results:All of 668 cases were included in the trial, but 618 cases were in complete conformity to the design plan (305 cases received UBLIN ?30 therapy and 313 cases received NovoMix ?30 therapy). At the end of 24-week treatment period, HbA 1c in UBLIN ?30 group and NovoMix ?30 group decreased by (1.38±1.33)% and (1.37±1.53)%, respectively, compared with the pre-treatment period, and the differences in the post-treatment change values were not statistically significant ( P>0.05). FPG decreased by (2.28±3.76) mmol/L and (1.67±3.55) mmol/L in the two groups, respectively, and the difference between groups in the decreasing values was statistically significant ( P=0.03). The 2hPG decreased by (3.22±5.38) mmol/L and (2.78±4.83) mmol/L in UBLIN ?30 group and NovoMix ?30 group, respectively, and the difference in the decrease was not statistically significant ( P=0.27). Moreover, the incidence of hypoglycemic events was 45.6% (151/331) and 43.8% (146/333) in UBLIN ?30 group and NovoMix ?30 group, respectively, and the incidence of other adverse reactions was 0.9% (3/331) and 0.9% (3/333), respectively. Conclusions:UBLIN ?30 provided similar glycemic control and safety profiles to NovoMix ?30, indicating that UBLIN ?30 is a suitable therapeutic option in clinical practice.